European urology open science · 2026
Electrical Pudendal Nerve Stimulation as an Initial Neuromodulation Strategy for Neurogenic Urinary Retention.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Tian, Xu Jiayi, Wang Siyou, Lv Jianwei, Huang Zouqin
Аннотация
BACKGROUND AND OBJECTIVE: Chronic neurogenic urinary retention often requires assisted emptying and remains challenging to treat. We evaluated whether electrical pudendal nerve stimulation (EPNS) improves bladder emptying and compared short-term outcomes with a standard sacral neuromodulation (SNM) test stimulation strategy.
METHODS: In this prospective, multicenter, assessor-masked study, 70 adults with chronic refractory neurogenic nonobstructive urinary retention received either EPNS (12 sessions over 4 wk) or a standard 4-wk continuous SNM test phase using a percutaneously placed S3 lead. The primary outcome was the percentage change from baseline in postvoid residual urine volume (PVR) at 4 wk. Secondary outcomes included changes in International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms and Quality of Life scores. Analyses used linear mixed models; propensity score matching was prespecified as a sensitivity analysis.
KEY FINDINGS AND LIMITATIONS: At 4 wk, the adjusted PVR improvement rate was 68% with EPNS versus 51% with SNM (between-group difference 17 percentage points; 95% confidence interval 5-29; p = 0.008). Improvements in symptom and quality of life scores also favored EPNS (p < 0.001 for both). Limitations include nonrandom treatment allocation and short follow-up.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Outpatient EPNS produced clinically meaningful short-term improvements in bladder emptying and patient-reported outcomes without implantation, supporting consideration of EPNS as an initial step in a stepped neuromodulation pathway for neurogenic urinary retention.
METHODS: In this prospective, multicenter, assessor-masked study, 70 adults with chronic refractory neurogenic nonobstructive urinary retention received either EPNS (12 sessions over 4 wk) or a standard 4-wk continuous SNM test phase using a percutaneously placed S3 lead. The primary outcome was the percentage change from baseline in postvoid residual urine volume (PVR) at 4 wk. Secondary outcomes included changes in International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms and Quality of Life scores. Analyses used linear mixed models; propensity score matching was prespecified as a sensitivity analysis.
KEY FINDINGS AND LIMITATIONS: At 4 wk, the adjusted PVR improvement rate was 68% with EPNS versus 51% with SNM (between-group difference 17 percentage points; 95% confidence interval 5-29; p = 0.008). Improvements in symptom and quality of life scores also favored EPNS (p < 0.001 for both). Limitations include nonrandom treatment allocation and short follow-up.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Outpatient EPNS produced clinically meaningful short-term improvements in bladder emptying and patient-reported outcomes without implantation, supporting consideration of EPNS as an initial step in a stepped neuromodulation pathway for neurogenic urinary retention.